Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 28;276:119437. doi: 10.1016/j.lfs.2021.119437

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 2 — The number of Treg cells in Nanocurcumin and placebo-treated groups in mild and severe COVID-19 patients. A. The results pertaining to the flow cytometry analysis of the Nanocurcumin and placebo-treated patients with mild and severe COVID-19, which indicated the percentage of CD4+ CD25+ FoxP3+ (Treg) cells among the total CD4+ T cell population. B. Nanocurcumin could significantly increase the frequency of Treg cells in the Nanocurcumin-treated group in mild COVID-19 patients after treatment vs. before treatment (P = 0.0049). C. In severe patients, considerable enhance was found in the number of Tregs in Nanocurcumin-treated patients after treatment vs. before treatment (P = 0.0085). No significant differences were observed in the placebo-treated group in both mild and severe patients after and before treatment (P = 0.9 and P = 0.461, respectively). Mild patient group, n = 40; severe patient group, n = 40; Nanocurcumin treated group, n = 20; placebo-treated group, n = 20. Results are given as, mean ± SD. P < 0.05 describes statistically significant. COVID-19, Coronavirus disease 2019; Treg, T-regulatory cell.